immatics biotechnologies GmbH (IMTXW) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

immatics biotechnologies GmbH (IMTXW) Healthcare & Pipeline Overview

Immatics N.V. is a clinical-stage biopharmaceutical company specializing in T cell redirecting immunotherapies for solid tumors. Utilizing proprietary adoptive cell therapies and TCR Bispecifics, the company is advancing a pipeline of novel cancer treatments, including lead candidates IMA203 and IMA401, supported by strategic collaborations in the oncology sector.

What Is the Investment Thesis for IMTXW?

Immatics N.V. presents a research-stage investment profile centered on its innovative T cell redirecting immunotherapy pipeline for solid tumors. Key value drivers include the advancement of lead candidates IMA203 and IMA401, both in Phase 1b clinical trials, which could de-risk the pipeline with positive data readouts. The company's proprietary XPRESIDENT technology platform for target discovery provides a competitive advantage in identifying novel and relevant tumor targets. Strategic collaborations with MD Anderson Cancer Center, Celgene Corporation, and Genmab A/S provide non-dilutive funding, validation, and shared development expertise, crucial for a company with a reported market capitalization of $0.00 billion and a profit margin of -574.9%. While the gross margin stands at 100.0% due to the clinical stage without product sales, significant R&D expenditures are expected. The beta of 0.82 suggests lower volatility compared to the broader market, yet the inherent risks of clinical trial success and regulatory approvals remain paramount for future valuation.

Based on FMP financials and quantitative analysis

IMTXW Key Highlights

Market Capitalization of $0.00 billion, reflecting its early-stage development and potential for future growth based on pipeline success.

• Profit Margin of -574.9%, typical for a clinical-stage biopharmaceutical company heavily investing in research and development without commercial product sales.
• Gross Margin of 100.0%, indicating minimal or no cost of goods sold as the company is primarily focused on R&D rather than manufacturing and selling commercial products.
• Beta of 0.82, suggesting the stock has historically exhibited lower volatility compared to the overall market, though this can change with pipeline developments.
• A workforce of 554 employees, demonstrating a substantial commitment to its research and development operations and clinical trial management.

Who Are IMTXW's Competitors?

IMTXW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IMTXW's Key Strengths?

Proprietary XPRESIDENT technology platform for precise target discovery, a key differentiator in T cell immunotherapy.

• Diverse pipeline with multiple candidates in clinical (Phase 1b) and preclinical stages across two distinct modalities (ACT and TCR Bispecifics).
• Strong strategic collaborations with major players like MD Anderson Cancer Center, Celgene, and Genmab, providing validation and resources.
• Focus on solid tumors, addressing a significant unmet medical need in oncology.

What Are IMTXW's Weaknesses?

Clinical-stage company with no commercialized products, leading to a negative profit margin (-574.9%) and reliance on funding.

• High capital expenditure required for ongoing research, development, and clinical trials.
• Pipeline remains in early clinical stages (Phase 1b), with long development timelines and inherent risks of failure.
• Market capitalization of $0.00 billion indicates a very early-stage or specific class of shares, potentially limiting liquidity or broad investor appeal.

What Could Drive IMTXW Stock Higher?

IMTXW catalyst: Release of Phase 1b clinical trial data for IMA203, targeting solid tumors, which could provide early validation of the therapy's safety and efficacy profile.

• Advancement of IMA401, a TCR Bispecific product, through its Phase 1b clinical trial, with potential for initial data readouts influencing future development pathways.
• Progress in strategic collaborations with MD Anderson Cancer Center, Celgene Corporation, and Genmab A/S, potentially leading to new research milestones or expanded development activities.
• Initiation of further clinical trials for preclinical candidates like IMA204 or IMA30x, signaling pipeline expansion and long-term growth prospects.

What Are the Key Risks for IMTXW?

Financial-distress signal — its Altman Z-Score of -0.96 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-45.4%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• High clinical trial failure rates, as a significant percentage of drug candidates, especially in oncology, do not successfully complete all phases of clinical development.
• Significant capital requirements and negative profit margin (-574.9%) necessitate continuous funding, with potential for future equity dilution if additional capital raises are required.
• Regulatory hurdles and lengthy approval processes, which can delay or prevent the commercialization of new therapies even if clinical data is positive.
• Intense competition within the T cell immunotherapy and broader oncology markets from established pharmaceutical companies and other biotechnology firms.
• Dependence on the success of strategic partnerships; any changes or termination of collaborations could significantly impact financial resources and development timelines.

What Are the Growth Opportunities for IMTXW?

• Growth opportunity 1: **Advancement of Lead Clinical Candidates** The progression of IMA203 and IMA401 through Phase 1b clinical trials represents a significant growth opportunity. Positive data readouts from these trials, which target solid tumors, could validate Immatics' therapeutic approach and proprietary technology. Successful advancement would de-risk the pipeline, attract further investment, and potentially lead to expanded clinical development or new strategic partnerships. The global oncology market, valued at hundreds of billions of dollars, provides a vast addressable market for effective new therapies, with T-cell immunotherapies being a rapidly growing segment expected to expand significantly over the next decade.
• Growth opportunity 2: **Expansion of Proprietary XPRESIDENT Platform** Immatics' proprietary XPRESIDENT technology platform is a key differentiator for target discovery. Expanding the application and leveraging this platform to identify novel, highly specific tumor targets for both ACT and TCR Bispecifics modalities could lead to a broader and more robust pipeline. This platform's ability to identify targets with high accuracy could accelerate preclinical development and improve the probability of success in clinical trials, opening new therapeutic avenues and potentially attracting additional collaborations with pharmaceutical partners seeking innovative target identification capabilities. The timeline for new target identification and subsequent preclinical development typically spans several years.
• Growth opportunity 3: **Strategic Collaborations and Partnerships** The company's existing strategic collaborations with MD Anderson Cancer Center, Celgene Corporation, and Genmab A/S are crucial for shared development costs, access to expertise, and potential milestone payments. Expanding these partnerships or forging new ones with other major pharmaceutical companies or research institutions could provide additional funding, accelerate development timelines, and broaden the therapeutic reach of Immatics' technologies. Such collaborations often include upfront payments, research funding, and potential milestone payments upon achieving specific development or regulatory goals, providing non-dilutive capital and market validation. The impact of new collaborations can be immediate through upfront payments and long-term through shared development successes.
• Growth opportunity 4: **Development of Allogeneic Cell Therapies** The preclinical development of IMA30x, an allogeneic cellular therapy product candidate, represents a substantial long-term growth opportunity. Allogeneic (off-the-shelf) cell therapies offer significant advantages over autologous (patient-specific) therapies, including scalability, reduced manufacturing complexity, and potentially lower costs, making them more accessible to a wider patient population. The market for allogeneic cell therapies is projected to grow substantially, driven by these practical benefits. Successful development of IMA30x could position Immatics as a leader in this evolving segment, potentially opening up a much larger market share compared to autologous approaches. This is a longer-term opportunity, with clinical trials likely several years away.
• Growth opportunity 5: **Targeting Tumor Stroma with IMA204** The preclinical development of IMA204, which targets tumor stroma, offers a unique approach to cancer treatment. The tumor stroma, the supportive tissue surrounding a tumor, often acts as a barrier to effective drug delivery and immune cell infiltration. By targeting the stroma, IMA204 aims to create a more permissive environment for anti-tumor immune responses and other therapies. This innovative strategy could address a significant challenge in treating solid tumors and potentially enhance the efficacy of existing treatments. If successful, this approach could open up new therapeutic paradigms and address difficult-to-treat cancers, providing a distinct competitive advantage. This is a preclinical stage asset, suggesting a longer development timeline for clinical validation.

What Threats Does IMTXW Face?

• High clinical trial failure rates inherent in biopharmaceutical development, particularly in oncology.
• Intense competition from other biotechnology and pharmaceutical companies developing similar T cell immunotherapies and cancer treatments.
• Regulatory hurdles and lengthy approval processes required for new drug candidates.
• Potential for intellectual property challenges or the emergence of superior competing technologies.
• Dependence on continued funding and successful capital raises to sustain extensive R&D efforts.

What Are IMTXW's Competitive Advantages?

• Proprietary XPRESIDENT technology platform for identifying novel and highly specific tumor-associated targets, offering a competitive edge in target discovery.
• Diverse pipeline of T cell redirecting immunotherapies across two distinct modalities (ACT and TCR Bispecifics), providing multiple shots on goal for treating solid tumors.
• Strategic collaborations with leading academic institutions and pharmaceutical companies, validating its technology and providing access to resources and expertise.
• Extensive intellectual property portfolio protecting its targets, therapeutic candidates, and development processes in the complex field of T cell immunotherapy.
• Deep scientific expertise and specialized R&D capabilities in T cell biology and oncology, built by a team of 554 employees.

What Does IMTXW Do?

Immatics N.V. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative T cell redirecting immunotherapies for the treatment of cancer, primarily targeting solid tumors within the United States market. Headquartered in Tübingen, Germany, the company employs 554 individuals focused on advancing its therapeutic pipeline. Immatics operates with two distinct treatment modalities: Adoptive Cell Therapies (ACT) and antibody-like T Cell Receptor (TCR) Bispecifics. The ACT pipeline includes IMA203, which targets solid tumors and is currently in Phase 1b clinical trials, alongside IMA203CD8, another cell therapy product also in Phase 1b. Further in the preclinical stage are IMA204, designed to target tumor stroma, and IMA30x, an allogeneic cellular therapy product candidate, representing potential future advancements in cell-based cancer treatment. Concurrently, the TCR Bispecifics platform features IMA401, which has progressed to Phase 1b clinical trials, and earlier-stage preclinical candidates IMA402 and IMA403. A cornerstone of Immatics' strategy involves strategic collaborations to accelerate its research and development efforts. The company has established significant partnerships, including an agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies. Additionally, Immatics collaborates with Celgene Corporation to develop novel adoptive cell therapies targeting various cancers, and with Genmab A/S to develop T cell engaging bispecific immunotherapies for multiple cancer indications. These collaborations underscore Immatics' commitment to leveraging external expertise and resources to bring its innovative immunotherapies to patients.

What Products and Services Does IMTXW Offer?

• Discover and develop T cell redirecting immunotherapies for cancer.
• Focus on treating solid tumors, a challenging area in oncology.
• Utilize two main treatment modalities: Adoptive Cell Therapies (ACT) and TCR Bispecifics.
• Advance a pipeline of product candidates, including IMA203 and IMA401 in Phase 1b clinical trials.
• Develop preclinical candidates like IMA204 (targeting tumor stroma) and IMA30x (allogeneic cell therapy).
• Engage in strategic collaborations with major institutions like MD Anderson Cancer Center and pharmaceutical companies such as Celgene and Genmab.
• Leverage proprietary technology, such as the XPRESIDENT platform, for target discovery.

How Does IMTXW Make Money?

• Primarily generates revenue through strategic collaboration agreements, which often include upfront payments, research funding, and potential milestone payments upon achieving specific development or regulatory goals.
• Invests heavily in research and development to advance its proprietary pipeline of T cell immunotherapies through preclinical and clinical stages.
• Aims for future revenue generation from the commercialization of successful drug candidates, either independently or through licensing agreements with pharmaceutical partners.
• Focuses on creating intellectual property around novel targets and therapeutic candidates to secure long-term value.

What Industry Does IMTXW Operate In?

Immatics N.V. operates within the highly dynamic and competitive biotechnology industry, specifically focusing on oncology and T cell immunotherapies. This segment of the healthcare sector is characterized by intense research and development, significant capital requirements, and a high-risk, high-reward profile. The broader market trend indicates a growing emphasis on precision medicine and immunotherapies, particularly those leveraging the body's own immune system to fight cancer. Immatics' focus on T cell receptor (TCR)-based immunotherapies positions it within a cutting-edge area, aiming to address unmet needs in solid tumors, which often present challenges for conventional treatments. The competitive landscape includes numerous established pharmaceutical companies and emerging biotechs also developing cell therapies and bispecific antibodies. Immatics differentiates itself through its proprietary XPRESIDENT technology platform for target discovery and its dual approach with Adoptive Cell Therapies (ACT) and TCR Bispecifics, aiming to develop best-in-class therapies.

Who Are IMTXW's Key Customers?

• Ultimately, cancer patients suffering from solid tumors, for whom current treatments may be insufficient.
• Strategic pharmaceutical partners (e.g., Celgene, Genmab) seeking innovative oncology assets and technologies for their pipelines.
• Research institutions (e.g., MD Anderson Cancer Center) collaborating on the development of advanced cell therapies.
• Oncologists and healthcare providers who would prescribe and administer the company's approved therapies in the future.

immatics biotechnologies GmbH (IMTXW) Valuation Context

Relative to its peer group, IMTXW's quantitative score of 53/100 is below the peer average of 76/100.

IMTXW Revenue & Earnings Trend

In Q1 2026, IMTXW generated $7.6M in top-line revenue, marking a sequential decrease of 61.5%. The company recorded a net loss of $57.8M, with diluted EPS of $-0.43. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, IMTXW averaged $-0.43 in diluted EPS.

Company Profile

immatics biotechnologies GmbH operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Tübingen, US. The company is led by CEO Harpreet Singh. IMTXW has traded publicly since 2020.

Return on equity for immatics biotechnologies GmbH stands at -45.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -42.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -19.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.54 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -19.2%, the inverse of the P/E and a quick read on earnings relative to price.

immatics biotechnologies GmbH's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.96 places it in the distress zone, a signal of elevated financial risk.

immatics biotechnologies GmbH has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 50.1% above estimates on average.

Wall Street analysts project immatics biotechnologies GmbH revenue of about $60.1M for fiscal 2026, with EPS near $-1.38. The estimate reflects 6 contributing analysts.

IMTXW Financials

IMTXW Latest News

No recent news available for IMTXW.

IMTXW Analyst Consensus

IMTXW MoonshotScore

immatics biotechnologies GmbH Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources